Your browser doesn't support javascript.
loading
Long-term control or possible cure? Treatment of stage D2 prostate cancer under chemotherapy using cisplatin and estramustine phosphate followed by maximal androgen blockade.
Urakami, Shinji; Shiina, Hiroaki; Sumura, Masahiro; Honda, Satoshi; Wake, Koji; Hiraoka, Takeo; Inoue, Shogo; Ishikawa, Noriyoshi; Igawa, Mikio.
Affiliation
  • Urakami S; Department of Urology, Shimane University School of Medicine, 89-1 Enya-cho, Izumo 693-8501, Japan. shinurakami@ybb.ne.jp
Int Urol Nephrol ; 40(2): 365-8, 2008.
Article in En | MEDLINE | ID: mdl-18092143
ABSTRACT
Metastatic prostate cancer (PC) is incurable by androgen deprivation therapy alone, due to the presence of androgen-independent/supersensitive cells in hormone-naive PC. A 67-year-old man was diagnosed with PC (Gleason score, 5 + 4) with multiple bone metastases. He was treated by chemohormonal therapy with cisplatin and estramustine phosphate (EMP) followed by maximal androgen blockade, and showed a complete response. As of the time of writing, no clinical or prostate-specific antigen recurrence has been observed for over 15 years, despite cessation of the treatment. This is the first report to indicate a possible cure of metastatic PC by chemohormonal therapy combined with appropriate anti-tumor drugs targeted to both androgen-independent and -dependent clones before the hormone-refractory state.
Subject(s)
Search on Google
Database: MEDLINE Main subject: Prostatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Cisplatin / Antineoplastic Agents, Hormonal / Estramustine / Androgen Antagonists / Antineoplastic Agents Limits: Aged / Humans / Male Language: En Year: 2008 Type: Article
Search on Google
Database: MEDLINE Main subject: Prostatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Cisplatin / Antineoplastic Agents, Hormonal / Estramustine / Androgen Antagonists / Antineoplastic Agents Limits: Aged / Humans / Male Language: En Year: 2008 Type: Article